Michael Wolff Jensen
General Counsel chez ASCENDIS PHARMA A/S
Fortune : 291 909 $ au 31/03/2024
Profil
M. Michael Wolff Jensen est président du conseil d'administration de Vicore Pharma Holding AB, directeur général de Miwo Invest ApS, président du conseil d'administration de Xspray Pharma AB, président du conseil d'administration d'Ascendis Pharma Endocrinology Division A/S, président, directeur juridique et vice-président principal d'Ascendis Pharma A/S, président d'Ascendis Pharma Bone Diseases A/S et président d'Ascendis Pharma Growth Disorders AS. Il est membre du conseil d'administration de Visen Pharmaceuticals (Shanghai) Co. Ltd. Auparavant, M. Jensen a occupé les postes de président du conseil d'administration d'Eurocine Vaccines AB, de directeur des partenariats en France de DONG Energy A/S, de directeur financier et de vice-président exécutif de LifeCycle Pharma A/S, de directeur financier et de vice-président principal de Genmab A/S, de président et de directeur général d'EMF Industries A/S, de président de MWJ Invest AB, de président de Paradis A/S et de président de Vanx ApS. Il a également été membre du conseil d'administration d'Azanta A/S. Il a obtenu son diplôme d'études supérieures à l'université de Copenhague.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASCENDIS PHARMA A/S
0,00% | 31/12/2023 | 1 931 ( 0,00% ) | 291 909 $ | 31/03/2024 |
Postes actifs de Michael Wolff Jensen
| Sociétés | Poste | Début |
|---|---|---|
| ASCENDIS PHARMA A/S | General Counsel | 01/06/2013 |
Miwo Invest ApS
 Miwo Invest ApS Miscellaneous Commercial ServicesCommercial Services Miwo Invest ApS owns and manages shares and ownership interests in other companies, as well as run consulting business within strategic business development, business strategy, financing, and investment. The company was founded by Michael Wolff Jensen on January 28, 2014 and is headquartered in Charlottenlund, Denmark. | Chief Executive Officer | 28/01/2014 |
| Ascendis Pharma Ophthalmology Division A/S | Chairman | - |
| Ascendis Pharma, Inc. | Director/Board Member | - |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Chairman | 08/01/2021 |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Chairman | - |
| Ascendis Pharma Growth Disorders AS | Chairman | - |
| Ascendis Pharma Bone Diseases A/S | Chairman | - |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Director/Board Member | 01/05/2021 |
| ░░░░░░░░ ░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Michael Wolff Jensen
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Michael Wolff Jensen
| University of Copenhagen | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| EUROCINE VACCINES AB | Health Technology |
| GENMAB A/S | Health Technology |
| ORSTED A/S | Utilities |
| ASCENDIS PHARMA A/S | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| VICORE PHARMA HOLDING AB | Health Technology |
| Entreprise privées | 16 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Vicore Pharma AB
Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Health Technology |
| Paradis A/S | |
| EMF Industries A/S | |
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | Health Technology |
| MWJ Invest AB | |
| Ascendis Pharma, Inc. | |
Miwo Invest ApS
Miwo Invest ApS Miscellaneous Commercial ServicesCommercial Services Miwo Invest ApS owns and manages shares and ownership interests in other companies, as well as run consulting business within strategic business development, business strategy, financing, and investment. The company was founded by Michael Wolff Jensen on January 28, 2014 and is headquartered in Charlottenlund, Denmark. | Commercial Services |
| Vanx ApS | |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Health Technology |
| Ascendis Pharma Bone Diseases A/S | |
| Ascendis Pharma Ophthalmology Division A/S | |
| Ascendis Pharma Oncology Division A/S | |
| Ascendis Pharma Growth Disorders AS | |
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
